Jade Biosciences
Yahoo Finance • 29 days ago
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the po... Full story
Yahoo Finance • last month
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ... Full story
Yahoo Finance • 2 months ago
Jade Biosciences Posts Wider Loss in Q2
Key Points Jade Biosciences reported a net loss per share of $0.86 (GAAP) for Q2 2025. The company missed analyst GAAP EPS estimates by $0.43, with the net loss per share widening significantly year over year. Research and development spe... Full story
Yahoo Finance • 2 months ago
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to... Full story
Yahoo Finance • 3 months ago
Jefferies initiates Jade Biosciences stock with Buy rating on IgAN treatment
Investing.com - Jefferies initiated coverage on Jade Biosciences (NASDAQ:JBIO), currently trading at $9.82 with a market cap of $317 million, with a Buy rating and a $16.00 price target on Monday. According to InvestingPro data, analysts’... Full story
Yahoo Finance • 3 months ago
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ... Full story
Yahoo Finance • 3 months ago
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announc... Full story
Yahoo Finance • 4 months ago
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation
Guggenheim upgraded Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy on Monday, setting a price target of $14.00 for the biotechnology company. The stock, currently trading at $6.76, has experienced a challenging week with a 12% decline.... Full story
Yahoo Finance • 4 months ago
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic... Full story
Yahoo Finance • 4 months ago
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announc... Full story
